Filing Details

Accession Number:
0001140361-12-036291
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-08-10 14:30:20
Reporting Period:
2012-08-08
Filing Date:
2012-08-10
Accepted Time:
2012-08-10 14:30:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1023869 Merilee Raines One Idexx Drive
Westbrook ME 04092
Executive Vp & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-08-08 2,032 $38.34 173,053 No 4 M Direct
Common Stock Acquisiton 2012-08-08 5,694 $17.14 178,747 No 4 M Direct
Common Stock Disposition 2012-08-08 6,906 $88.77 171,841 No 4 S Direct
Common Stock Disposition 2012-08-08 820 $89.43 171,021 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Options (right to buy) Disposition 2012-08-08 2,032 $0.00 2,032 $38.34
Common Stock Non-Qualified Stock Options (right to buy) Disposition 2012-08-08 5,694 $0.00 5,694 $17.14
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,160 2013-02-13 No 4 M Direct
28,470 2014-02-06 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 13,430 Indirect by Charitable Remainder Unitrust
Footnotes
  1. The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 04/26/2012.
  2. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $88.30 to $89.29, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
  3. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $89.30 to $89.55, inclusive.
  4. Grant of options to buy shares of common stock becomes exercisable as to 2,960 shares on 02/14/2007, 02/14/2008, 02/14/2009, and 02/14/2010, and the remaining 352 shares on 02/14/2011.
  5. Grant of options to buy shares of common stock becomes exercisable as to 8,000 shares on 02/06/2004, 02/06/2005, 02/06/2006, and 02/06/2007, and the remaining 2,164 shares on 02/06/2008.